Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases


Cancer research is increasingly dependent of patient-derived xenograft model (PDX). However, a major point of concern regarding the PDX model remains the replacement of the human stroma with murine counterpart. In the present work we aimed at clarifying the significance of the human-to-murine stromal replacement for the fidelity of colorectal cancer (CRC) and liver metastasis (CRC-LM) PDX model. We have conducted a comparative metabolic analysis between 6 patient tumors and corresponding PDX across 4 generations. Metabolic signatures of cancer cells and stroma were measured separately by MALDI-imaging, while metabolite changes in entire tumors were quantified using mass spectrometry approach. Measurement of glucose metabolism was also conducted in vivo using [18F]-fluorodeoxyglucose (FDG) and positron emission tomography (PET). In CRC/CRC-LM PDX model, human stroma was entirely replaced at the second generation. Despite this change, MALDI-imaging demonstrated that the metabolic profiles of both stromal and cancer cells remained stable for at least four generations in comparison to the original patient material. On the tumor level, profiles of 86 water-soluble metabolites as well as 93 lipid mediators underlined the functional stability of the PDX model. In vivo PET measurement of glucose uptake (reflecting tumor glucose metabolism) supported the ex vivo observations. Our data show for the first time that CRC/CRC-LM PDX model maintains the functional stability at the metabolic level despite the early replacement of the human stroma by murine cells. The findings demonstrate that human cancer cells actively educate murine stromal cells during PDX development to adopt the human-like phenotype.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5


  1. 1.

    Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73:5315–9.

    CAS  Article  Google Scholar 

  2. 2.

    Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9:338–50.

    CAS  Article  Google Scholar 

  3. 3.

    Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, et al. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science. 1989;246:1046–8.

    CAS  Article  Google Scholar 

  4. 4.

    Houghton JA, Maroda SJ Jr., Phillips JO, Houghton PJ. Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice. Cancer Res. 1981;41:144–9.

    CAS  PubMed  Google Scholar 

  5. 5.

    Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc. 2009;4:1670–80.

    CAS  Article  Google Scholar 

  6. 6.

    Werner-Klein M, Proske J, Werno C, Schneider K, Hofmann HS, Rack B, et al. Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients. PLoS ONE 2014;9:e97860.

    Article  Google Scholar 

  7. 7.

    Walsh NC, Kenney LL, Jangalwe S, Aryee KE, Greiner DL, Brehm MA, et al. Humanized mouse models of clinical disease. Annu Rev Pathol. 2017;12:187–215.

    CAS  Article  Google Scholar 

  8. 8.

    DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17:1514–20.

    CAS  Article  Google Scholar 

  9. 9.

    Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73:4885–97.

    CAS  Article  Google Scholar 

  10. 10.

    Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116–30.

    CAS  Article  Google Scholar 

  11. 11.

    Cassidy JW, Caldas C, Bruna A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 2015;75:2963–8.

    CAS  Article  Google Scholar 

  12. 12.

    Hylander BL, Punt N, Tang H, Hillman J, Vaughan M, Bshara W, et al. Origin of the vasculature supporting growth of primary patient tumor xenografts. J Transl Med. 2013;11:110.

    Article  Google Scholar 

  13. 13.

    Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther. 1999;10:2941–52.

    CAS  Article  Google Scholar 

  14. 14.

    Sanz L, Cuesta AM, Salas C, Corbacho C, Bellas C, Alvarez-Vallina L. Differential transplantability of human endothelial cells in colorectal cancer and renal cell carcinoma primary xenografts. Lab Invest. 2009;89:91–7.

    CAS  Article  Google Scholar 

  15. 15.

    Chiavarina B, Turtoi A. Collaborative and Defensive Fibroblasts in Tumor Progression and Therapy Resistance. Curr Med Chem. 2017;24:2846–2859. 

    Article  Google Scholar 

  16. 16.

    Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16:582–98.

    CAS  Article  Google Scholar 

  17. 17.

    Lou S, Balluff B, Cleven AH, Bovee JV, McDonnell LA. An experimental guideline for the analysis of histologically heterogeneous tumors by MALDI-TOF mass spectrometry imaging. Biochimica et Biophysica Acta. 2017;1865:957–966.

    CAS  Article  Google Scholar 

  18. 18.

    McDonnell LA, Walch A, Stoeckli M, Corthals GL. MSiMass list: a public database of identifications for protein MALDI MS imaging. J Proteome Res. 2014;13:1138–42.

    CAS  Article  Google Scholar 

  19. 19.

    Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, et al. Metabolic heterogeneity signature of primary treatment-naive prostate cancer. Oncotarget. 2017;8:25928–41.

    PubMed  PubMed Central  Google Scholar 

  20. 20.

    Amos-Landgraf JM, Heijmans J, Wielenga MC, Dunkin E, Krentz KJ, Clipson L, et al. Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones. Proc Natl Acad Sci USA. 2014;111:16514–9.

    CAS  Article  Google Scholar 

  21. 21.

    Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol. 2010;195:310–20.

    Article  Google Scholar 

  22. 22.

    Sha W, Ye H, Iwamoto KS, Wong KP, Wilks MQ, Stout D, et al. Factors affecting tumor (18) F-FDG uptake in longitudinal mouse PET studies. EJNMMI Res. 2013;3:51.

    Article  Google Scholar 

  23. 23.

    Valtorta S, Moro M, Prisinzano G, Bertolini G, Tortoreto M, Raccagni I, et al. Metabolic evaluation of non-small cell lung cancer patient-derived xenograft models using 18F-FDG PET: a potential tool for early therapy response. J Nucl Med. 2017;58:42–7.

    CAS  Article  Google Scholar 

  24. 24.

    Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthr Cartil. 2012;20:256–60.

    CAS  Article  Google Scholar 

  25. 25.

    Blomme A, Costanza B, de Tullio P, Thiry M, Van Simaeys G, Boutry S, et al. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer. Oncogene. 2017;36:2116–2130.

    Article  Google Scholar 

  26. 26.

    Fueger BJ, Czernin J, Hildebrandt I, Tran C, Halpern BS, Stout D, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J Nucl Med. 2006;47:999–1006.

    CAS  PubMed  Google Scholar 

  27. 27.

    Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S–50S.

    CAS  Article  Google Scholar 

  28. 28.

    Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200.

    Article  Google Scholar 

  29. 29.

    van Velden FH, Cheebsumon P, Yaqub M, Smit EF, Hoekstra OS, Lammertsma AA, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging. 2011;38:1636–47.

    Article  Google Scholar 

Download references


The authors acknowledge the experimental support of Dr. Chantal Humblet, Mrs. Alice Marquet (GIGA-histology platform, ULg), Mr. Vincent Hennequière, Mrs. Naima Maloujahmoum (Metastasis Research Laboratory), Mrs. Yezza Ben Salah (Tumor Microenvironment and Resistance to Treatment Lab, IRCM), Mr. Nicolas Passon (CMMI) and Mrs. Mari-Aline Laute (CMMI). The authors are thankful to Dr. Stéphanie Gofflot (Biobank, University Hospital Liege) for providing patient material as well as the Cyclotron Unit of Erasme Hospital (Brussels, Belgium) for providing [18F]-FDG. Prof. Robert N. Muller (CMMI, Director of international partnerships) is thanked for his scientific input and support. Mr. Mathieu Roch (CMMI) is thanked for tumor volume measurements on MR images.This work was supported with grants from the University of Liège, National Fund for Scientific Research (FNRS) and Gunma University (GIAR Research Program for Omics-Based Medical Science). The CMMI is supported by the European Regional Development Fund (ERDF), the Walloon Region, the Fondation ULB, the Fonds Erasme and the “Association Vinçotte Nuclear” (AVN). GD is supported by the ERDF and the Walloon Region. Akeila Bellahcène is a Research Director at the FNRS. AT is a senior research fellow of the French National Institute of Health and Medical Research (INSERM) and is supported by LabEx MabImprove Starting Grant. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information



Corresponding author

Correspondence to Andrei Turtoi.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Additional information

Vincent Castronovo and Andrei Turtoi contributed equally to this work.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Blomme, A., Van Simaeys, G., Doumont, G. et al. Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases. Oncogene 37, 1237–1250 (2018).

Download citation

Further reading


Quick links